PriceSensitive

Psyched Wellness (CSE:PSYC) to remain ‘CALM’ during first pilot production run

Psychedelics
TSXV:PSYC
29 June 2022 15:15 (EDT)

Psyched Wellness Ltd. (PSYC) initial pilot production run for its first-to-market AME-1 product, ‘Calm’ is scheduled for July 7.

The product is presented as an extract which enables the mushroom’s ability to de-stress and facilitate restful sleep.

According to the company, the production of the product signals that the company is on track to transition from an R&D organization to a full-scale commercial consumer packaged goods (CPG) entity, generating revenue.

All Amanita Muscaria products produced by Psyched Wellness will be available over-the-counter and without a prescription.

Psyched hopes this will maximize distribution and listing potential. ‘Calm’ will be the first legal Amanita Muscaria mushroom product to be sold in North America.

COO of Psyched, Matthew Singh touched on the not so easy journey to get to this place. “Each calibration that improved our offering motivated the R&D, Operations, and Production teams to continue reformulating and optimizing until Calm reached its current form.”

“It was important for our team to stay focused and not rush what is arguably the most integral part of product development. Our entire company is excited to share this version of Calm with the world (starting with a release in the United States),” continued Singh.

In the future, the team is looking to produce a craft number of units that will be used to test all flavour profiles and share them with opinion leaders. Updates on the pilot run can be expected 24 to 48 hours after production.

Psyched Wellness Ltd. is a Canadian-based health supplements company with the objective to create premium mushroom-derived products. 

Psyched Wellness Ltd. (PSYC) is up over 15.30 per cent, trading at C$0.08 at 2:13 pm EST.

Related News